{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:38:23Z","timestamp":1792906703385,"version":"4.5.0"},"reference-count":112,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med Rep"],"DOI":"10.3892\/mmr.2026.14041","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:24:47Z","timestamp":1791890687000},"page":"1-20","source":"Crossref","is-referenced-by-count":0,"title":["Navigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review)"],"prefix":"10.3892","volume":"34","author":[{"given":"Hongguo","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingheng","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peisen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhong","family":"Che","sequence":"additional","affiliation":[{"name":"Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[{"name":"Research and Translational Center for Immunological Disorders, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankai","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, The Second Clinical Medical School of Shandong Medical and Pharmaceutical University, Yantai, Shandong 264100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"key20261025073058_b1-mmr-34-6-14041","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20261025073058_b2-mmr-34-6-14041","first-page":"e70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"key20261025073058_b3-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol"},{"key":"key20261025073058_b4-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced Renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"key20261025073058_b5-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat Med"},{"key":"key20261025073058_b6-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"key20261025073058_b7-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"key20261025073058_b8-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2026.02.011","article-title":"Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial","volume":"37","author":"Motzer","year":"2026","journal-title":"Ann Oncol"},{"key":"key20261025073058_b9-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"key20261025073058_b10-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.critrevonc.2013.12.003","article-title":"A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma","volume":"90","author":"Ismail","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20261025073058_b11-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"key20261025073058_b12-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","article-title":"The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer","volume":"8","author":"Kaelin","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"key20261025073058_b13-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s12672-026-04707-9","article-title":"Emerging roles for the epigenetic modifiers PBRM1, SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VHL","volume":"17","author":"Jixiang","year":"2026","journal-title":"Discov Oncol"},{"key":"key20261025073058_b14-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11684-025-1136-4","article-title":"Essential genetic mutations impair DNA damage repair and modulate tumor immune microenvironment in ccRCC","volume":"20","author":"He","year":"2026","journal-title":"MedScience"},{"key":"key20261025073058_b15-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-05-2670","article-title":"Regulation of E-cadherin expression by VHL and hypoxia-inducible factor","volume":"66","author":"Esteban","year":"2006","journal-title":"Cancer Res"},{"key":"key20261025073058_b16-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"key":"key20261025073058_b17-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2\u03b1 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"key20261025073058_b18-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","article-title":"A small-molecule antagonist of HIF2\u03b1 is efficacious in preclinical models of renal cell carcinoma","volume":"76","author":"Wallace","year":"2016","journal-title":"Cancer Res"},{"key":"key20261025073058_b19-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"key20261025073058_b20-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced Renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"key20261025073058_b21-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"189165","DOI":"10.1016\/j.bbcan.2024.189165","article-title":"Decoding PTEN regulation in clear cell renal cell carcinoma: Pathway for biomarker discovery and therapeutic insights","volume":"1879","author":"Alves","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"key20261025073058_b22-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1038\/s41401-022-00862-1","article-title":"PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma","volume":"43","author":"Liu","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"key20261025073058_b23-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1074\/jbc.M116.746875","article-title":"Individual bromodomains of Polybromo-1 contribute to chromatin association and tumor suppression in clear cell renal carcinoma","volume":"292","author":"Porter","year":"2017","journal-title":"J Biol Chem"},{"key":"key20261025073058_b24-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neo.2018.12.006","article-title":"Expression and mutation patterns of PBRM1, BAP1 and SETD2 mirror specific evolutionary subtypes in clear cell renal cell carcinoma","volume":"21","author":"Bihr","year":"2019","journal-title":"Neoplasia"},{"key":"key20261025073058_b25-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1093\/nar\/gkad072","article-title":"PBRM1 bromodomains associate with RNA to facilitate chromatin association","volume":"51","author":"De Silva","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"key20261025073058_b26-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"712765","DOI":"10.3389\/fonc.2021.712765","article-title":"Mutational analysis of PBRM1 and significance of PBRM1 mutation in Anti-PD-1 immunotherapy of clear cell renal cell carcinoma","volume":"11","author":"Aili","year":"2021","journal-title":"Front Oncol"},{"key":"key20261025073058_b27-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cancers12010016","article-title":"Prognostic and predictive value of PBRM1 in clear cell renal cell carcinoma","volume":"12","author":"Carril-Ajuria","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20261025073058_b28-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41467-020-15959-6","article-title":"PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma","volume":"11","author":"Liu","year":"2020","journal-title":"Nat Commun"},{"key":"key20261025073058_b29-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"key":"key20261025073058_b30-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jamaoncol.2019.3158","article-title":"Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma","volume":"5","author":"Braun","year":"2019","journal-title":"JAMA Oncol"},{"key":"key20261025073058_b31-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41418-022-01024-w","article-title":"BAP1 promotes the repair of UV-induced DNA damage via PARP1-mediated recruitment to damage sites and control of activity and stability","volume":"29","author":"Lee","year":"2022","journal-title":"Cell Death Differ"},{"key":"key20261025073058_b32-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3892\/ol.2024.14743","article-title":"Roles of deubiquitinases in urologic cancers (review)","volume":"28","author":"Wu","year":"2024","journal-title":"Oncol Lett"},{"key":"key20261025073058_b33-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/cncr.28521","article-title":"Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma","volume":"120","author":"Joseph","year":"2014","journal-title":"Cancer"},{"key":"key20261025073058_b34-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/2159-8290.CD-17-0292","article-title":"Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inactivation drive tumor grade","volume":"7","author":"Gu","year":"2017","journal-title":"Cancer Discov"},{"key":"key20261025073058_b35-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/ajcp\/aqaa176","article-title":"BAP1-mutated clear cell renal cell carcinoma","volume":"155","author":"Gallan","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"key20261025073058_b36-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1158\/0008-5472.CAN-17-3460","article-title":"SETD2 haploinsufficiency for microtubule methylation is an early driver of genomic instability in renal cell carcinoma","volume":"78","author":"Chiang","year":"2018","journal-title":"Cancer Res"},{"key":"key20261025073058_b37-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s43018-021-00316-3","article-title":"SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes","volume":"3","author":"Xie","year":"2022","journal-title":"Nat Cancer"},{"key":"key20261025073058_b38-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"7572","DOI":"10.1038\/s41467-023-43378-w","article-title":"SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer","volume":"14","author":"Rao","year":"2023","journal-title":"Nat Commun"},{"key":"key20261025073058_b39-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"647","DOI":"10.18632\/oncotarget.27288","article-title":"SETD2 loss sensitizes cells to PI3K\u03b2 and AKT inhibition","volume":"10","author":"Terzo","year":"2019","journal-title":"Oncotarget"},{"key":"key20261025073058_b40-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s42003-025-07695-8","article-title":"KDM5C and KDM5D mutations have different consequences in clear cell renal cell carcinoma cells","volume":"8","author":"M\u00fcller","year":"2025","journal-title":"Commun Biol"},{"key":"key20261025073058_b41-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"8674","DOI":"10.7150\/thno.60233","article-title":"Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis","volume":"11","author":"Zheng","year":"2021","journal-title":"Theranostics"},{"key":"key20261025073058_b42-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41698-024-00627-5","article-title":"NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity","volume":"8","author":"Xu","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"key20261025073058_b43-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/cancers17010064","article-title":"Role of NF2 mutation in the development of eleven different cancers","volume":"17","author":"Nouri","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20261025073058_b44-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/cancers15041316","article-title":"Downstream targets of VHL\/HIF-\u03b1 signaling in renal clear cell carcinoma progression: Mechanisms and therapeutic relevance","volume":"15","author":"Mazumder","year":"2023","journal-title":"Cancers (Basel)"},{"key":"key20261025073058_b45-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"key20261025073058_b46-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s12094-020-02292-z","article-title":"Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: A systematic review and meta-analysis","volume":"22","author":"Buti","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"key20261025073058_b47-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"key20261025073058_b48-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"key20261025073058_b49-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"102645","DOI":"10.1016\/j.ctrv.2023.102645","article-title":"Evolution of the HIF targeted therapy in clear cell renal cell carcinoma","volume":"121","author":"Golijanin","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"key20261025073058_b50-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2-VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med"},{"key":"key20261025073058_b51-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"key20261025073058_b52-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1158\/2159-8290.CD-17-0610","article-title":"Bap1 and Pbrm1: Determinants of tumor grade and mTOR activation in VHL-Deficient mouse models of renal cell carcinoma","volume":"7","author":"Leung","year":"2017","journal-title":"Cancer Discov"},{"key":"key20261025073058_b53-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1002\/ijc.28503","article-title":"Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor","volume":"134","author":"Santoni","year":"2014","journal-title":"Int J Cancer"},{"key":"key20261025073058_b54-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1158\/1535-7163.MCT-15-0170","article-title":"Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma","volume":"15","author":"Bridgeman","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"key20261025073058_b55-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10555-021-09996-w","article-title":"Lipid metabolism reprogramming in renal cell carcinoma","volume":"41","author":"Heravi","year":"2022","journal-title":"Cancer Metastasis Rev"},{"key":"key20261025073058_b56-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20261025073058_b57-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced Renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"key20261025073058_b58-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1023177","DOI":"10.3389\/fonc.2022.1023177","article-title":"The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"key20261025073058_b59-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"key":"key20261025073058_b60-mmr-34-6-14041","first-page":"100127","article-title":"Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma","volume":"19","author":"Pilskog","year":"2019","journal-title":"Cancer Treat Res Commun"},{"key":"key20261025073058_b61-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"10732748231155700","DOI":"10.1177\/10732748231155700","article-title":"Research progress of tumor microenvironment targeted therapy for clear cell renal cell carcinoma","volume":"30","author":"Huang","year":"2023","journal-title":"Cancer Control"},{"key":"key20261025073058_b62-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"653358","DOI":"10.3389\/fimmu.2021.653358","article-title":"Roles of the dynamic tumor immune microenvironment in the individualized treatment of advanced clear cell renal cell carcinoma","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"key20261025073058_b63-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"7636","DOI":"10.3390\/ijms27177636","article-title":"Crosstalk between mTOR and NF-\u03baB signaling pathways in clear cell renal cell carcinoma","volume":"27","author":"Glueck","year":"2026","journal-title":"Int J Mol Sci"},{"key":"key20261025073058_b64-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s00011-026-02363-x","article-title":"MLN4924 suppresses kidney renal clear cell carcinoma progression through coordinated inhibition of Cullin1 neddylation and PSMB10-associated NF-\u03baB inflammatory signaling","volume":"75","author":"Liu","year":"2026","journal-title":"Inflamm Res"},{"key":"key20261025073058_b65-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","article-title":"Novel therapies emerging in oncology to target the TGF-\u03b2 pathway","volume":"14","author":"Kim","year":"2021","journal-title":"J Hematol Oncol"},{"key":"key20261025073058_b66-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.drup.2023.100929","article-title":"Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers","volume":"67","author":"Jin","year":"2023","journal-title":"Drug Resist Updat"},{"key":"key20261025073058_b67-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/path.5022","article-title":"Genomic classifications of renal cell carcinoma: A critical step towards the future application of personalized kidney cancer care with pan-omics precision","volume":"244","author":"Hsieh","year":"2018","journal-title":"J Pathol"},{"key":"key20261025073058_b68-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10147-019-01528-5","article-title":"C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab","volume":"25","author":"Suzuki","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"key20261025073058_b69-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1200\/JCO.22.02623","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"41","author":"Motzer","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20261025073058_b70-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"key20261025073058_b71-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"key20261025073058_b72-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20261025073058_b73-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced Renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"key20261025073058_b74-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s41416-018-0061-6","article-title":"Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma","volume":"118","author":"Motzer","year":"2018","journal-title":"Br J Cancer"},{"key":"key20261025073058_b75-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20261025073058_b76-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur J Cancer"},{"key":"key20261025073058_b77-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20261025073058_b78-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): A phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20261025073058_b79-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.2147\/OTT.S145295","article-title":"Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma","volume":"10","author":"Gerendash","year":"2017","journal-title":"Onco Targets Ther"},{"key":"key20261025073058_b80-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"key20261025073058_b81-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.clgc.2016.04.011","article-title":"Outcomes in patients with metastatic renal cell carcinoma who develop Everolimus-Related hyperglycemia and hypercholesterolemia: Combined subgroup analyses of the RECORD-1 and REACT trials","volume":"14","author":"Bono","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"key20261025073058_b82-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur J Cancer"},{"key":"key20261025073058_b83-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced Renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"key20261025073058_b84-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"key20261025073058_b85-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.annonc.2026.02.017","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis of efficacy and safety from the phase III CheckMate 214 trial","volume":"37","author":"Choueiri","year":"2026","journal-title":"Ann Oncol"},{"key":"key20261025073058_b86-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: Final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"Choueiri","year":"2025","journal-title":"Ann Oncol"},{"key":"key20261025073058_b87-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20261025073058_b88-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3233\/KCA-190058","article-title":"A review of papillary renal cell carcinoma and MET inhibitors","volume":"3","author":"Rhoades Smith","year":"2019","journal-title":"Kidney Cancer"},{"key":"key20261025073058_b89-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"key20261025073058_b90-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S0140-6736(26)01089-5","article-title":"Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): An open-label, randomised, controlled, phase 3 trial","volume":"408","author":"Motzer","year":"2026","journal-title":"Lancet"},{"key":"key20261025073058_b91-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa2518245","article-title":"Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma","volume":"395","author":"Choueiri","year":"2026","journal-title":"N Engl J Med"},{"key":"key20261025073058_b92-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20261025073058_b93-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10637-020-01058-2","article-title":"A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy","volume":"39","author":"Choueiri","year":"2021","journal-title":"Invest New Drugs"},{"key":"key20261025073058_b94-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/jco.2009.27.15_suppl.5041","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20261025073058_b95-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"key20261025073058_b96-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"key20261025073058_b97-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicentre, open-label, randomised, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"key20261025073058_b98-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20261025073058_b99-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41588-024-01662-5","article-title":"Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression","volume":"56","author":"Hu","year":"2024","journal-title":"Nat Genet"},{"key":"key20261025073058_b100-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13244-025-02164-6","article-title":"From radiomics to radiogenomics: Decoding renal cell carcinoma biology for precision medicine, a narrative review","volume":"16","author":"He","year":"2025","journal-title":"Insights Imaging"},{"key":"key20261025073058_b101-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1007\/s00261-025-04963-3","article-title":"State of the art review of AI in renal imaging","volume":"50","author":"Sheikhy","year":"2025","journal-title":"Abdom Radiol (NY)"},{"key":"key20261025073058_b102-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma","volume":"26","author":"Courtney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20261025073058_b103-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/03007995.2018.1423960","article-title":"First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: Priming the tumor microenvironment for immunotherapy","volume":"34","author":"Tannir","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"key20261025073058_b104-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s40265-020-01327-7","article-title":"Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma","volume":"80","author":"Hirsch","year":"2020","journal-title":"Drugs"},{"key":"key20261025073058_b105-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"key20261025073058_b106-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10637-005-4543-z","article-title":"Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma","volume":"24","author":"Vuky","year":"2006","journal-title":"Invest New Drugs"},{"key":"key20261025073058_b107-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1761280","DOI":"10.3389\/fphar.2026.1761280","article-title":"Epithelial-mesenchymal transition and sunitinib resistance in renal cell carcinoma: Mechanisms and therapeutic strategies","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Pharmacol"},{"key":"key20261025073058_b108-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/24684570241303346","article-title":"Liquid biopsy for renal cell carcinoma: A comprehensive review of techniques, applications, and future prospects","volume":"8","author":"Jani","year":"2024","journal-title":"Kidney Cancer"},{"key":"key20261025073058_b109-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1458616","DOI":"10.3389\/fonc.2024.1458616","article-title":"Exosome in renal cell carcinoma progression and implications for targeted therapy","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"key20261025073058_b110-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"e2400667","DOI":"10.1200\/PO-24-00667","article-title":"Longitudinal testing of circulating tumor DNA in patients with metastatic renal cell carcinoma","volume":"8","author":"Basu","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"key20261025073058_b111-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.3390\/curroncol29080429","article-title":"Next wave of targets in the treatment of advanced renal cell carcinoma","volume":"29","author":"Cardenas","year":"2022","journal-title":"Curr Oncol"},{"key":"key20261025073058_b112-mmr-34-6-14041","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clgc.2013.07.004","article-title":"Considerations for the design of future clinical trials in metastatic renal cell carcinoma","volume":"12","author":"Escudier","year":"2014","journal-title":"Clin Genitourin Cancer"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:31:04Z","timestamp":1792906264000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mmr.2026.14041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":112,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.3892\/mmr.2026.14041","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}